Getting a GLP-1 Prescription Online: What to Know
Telehealth companies now offer these weight-loss medicines after a short online form. Here is what FDA labeling, the major trials, and clinical guidelines actually say — and how to spot a risky service.
By Wellness Wire Editorial
Weight-loss medicines known as GLP-1 drugs are now heavily advertised by telehealth companies that often promise a prescription after a short online questionnaire. Two are FDA-approved for weight management: Wegovy (semaglutide) and Zepbound (tirzepatide). Getting one online can be legitimate — but the details matter. This explainer sticks to FDA labeling, published clinical trials, and professional guidelines so you can ask sharper questions.
What these drugs are — and who they're for
FDA labeling limits these medicines to specific groups. They are approved for adults — and, for Wegovy, patients 12 and older — as an addition to a reduced-calorie diet and increased physical activity, not as a standalone fix. The approved starting points are based on body-mass index (BMI):
- A BMI of 30 kg/m² or higher (the range defined as obesity); or
- A BMI of 27 kg/m² or higher (overweight) plus at least one weight-related condition, such as high blood pressure, abnormal cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.
A careful telehealth prescriber should be confirming that you actually meet these criteria, rather than simply taking an order. That verification is one of the clearest signs of a legitimate service.
What the evidence shows
The headline results come from large randomized trials, the strongest kind of evidence. In the STEP 1 trial of 1,961 adults who had overweight or obesity but not diabetes, once-weekly semaglutide 2.4 mg plus lifestyle support produced an average weight change of about −14.9% over 68 weeks, compared with −2.4% for placebo. About 86% of people on semaglutide lost at least 5% of their body weight.
In SURMOUNT-1, which tested tirzepatide in 2,539 adults with obesity or overweight, average weight changes over 72 weeks were −15.0%, −19.5%, and −20.9% at the 5-, 10-, and 15-mg doses, versus −3.1% for placebo. (These are the figures from the trial's primary analysis; the manufacturer reported slightly larger numbers using a different statistical method.)
The benefits may go beyond the scale. In the SELECT trial of 17,604 adults who had established cardiovascular disease and overweight or obesity but not diabetes, semaglutide 2.4 mg reduced major cardiovascular events — such as heart attack and stroke — by 20% (6.5% of the treatment group versus 8.0% on placebo; hazard ratio 0.80). That result supported an added FDA indication for reducing cardiovascular risk in Wegovy.
These results reflect the drug plus structured lifestyle support in closely monitored patients — not a prescription on its own.
Two cautions are worth keeping in mind. The trial participants were carefully selected and monitored, and everyone received lifestyle support alongside the drug, so real-world results from a telehealth program may differ. Gastrointestinal side effects and dropouts were also common during the studies.
The risks and side effects
Both Wegovy and Zepbound carry an FDA Boxed Warning — its most serious kind — for a risk of thyroid C-cell tumors. They should not be used by anyone with a personal or family history of medullary thyroid carcinoma (a specific thyroid cancer) or the genetic condition MEN 2 (Multiple Endocrine Neoplasia syndrome type 2). Crucially, this warning comes from studies in rodents. FDA states plainly that it is unknown whether the drugs cause thyroid tumors in people — a precaution, not proof of a human cancer risk.
FDA labeling also lists other warnings and precautions to watch for:
- Acute pancreatitis (inflammation of the pancreas)
- Acute gallbladder disease
- Acute kidney injury, often triggered by dehydration from vomiting
- Low blood sugar, especially when combined with insulin or a sulfonylurea
- New or worsening depression or thoughts of suicide, which should be monitored
The most common side effects — affecting 5% or more of people — are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. Having a prescriber, and a way to reach one for follow-up questions, matters precisely because problems like these can come up.
Compounded and unapproved versions
Many telehealth ads feature "compounded" semaglutide or tirzepatide — versions mixed by a pharmacy rather than made by the brand-name manufacturers. FDA warns that these compounded products are not FDA-approved and "do not undergo FDA's review for safety, effectiveness and quality before they are marketed." As a rule, compounded drugs are meant to be used only when a patient's medical needs cannot be met by an approved product.
The legal room for these products has narrowed. FDA has declared the national semaglutide and tirzepatide shortages resolved and reminded compounders that they generally may not make copies of commercially available drugs — noting that even adding another ingredient, such as vitamin B12, can count as an impermissible copy. The agency has sent warning letters to companies marketing compounded GLP-1s illegally; a September 2025 letter cited compounded semaglutide and retatrutide, an investigational drug that is not FDA-approved at all. FDA has also warned about counterfeit Ozempic in the U.S. supply chain and about semaglutide sold online labeled "for research purposes" or "not for human consumption" — unknown in quality and possibly harmful. Its advice: fill prescriptions only at state-licensed pharmacies.
How to spot a legitimate service
One common point of confusion: GLP-1 drugs are not federally controlled substances, so the federal telemedicine rules that cover medicines like opioids do not apply, and prescribing them by telehealth alone is not banned nationally. As a general matter, though, state medical laws still require a real practitioner-patient relationship and a good-faith evaluation before any prescription — some states accept a live video visit, others require an initial in-person exam. Rules vary by state, so treat this as general guidance, not a fixed federal standard.
FDA publishes specific "red flags" for spotting a risky online seller. Be wary of a company that:
- Claims its compounded drug is the same as the FDA-approved version
- Offers deep discounts or prices that seem too good to be true
- Ships medicine without requiring screening and a prescription from a licensed doctor
- Has no licensed doctor available for follow-up questions
- Sends medicine with a fraudulent-looking or misspelled pharmacy name or label
Finally, legitimate GLP-1 treatment is ongoing, not a one-time purchase. The American Diabetes Association ranks semaglutide and tirzepatide among the most effective weight-loss medicines and advises that such medication generally continue after a goal weight is reached, because stopping tends to bring weight back along with rising cardiometabolic risk. A service built around a quick sale, with no plan for follow-up, is not set up for how these drugs are meant to be used. Bottom line: an online prescription can be reasonable when a licensed clinician confirms you qualify, reviews your risks, dispenses an FDA-approved drug from a licensed pharmacy, and stays available over time.
- 01 FDA Prescribing Information, Wegovy (semaglutide) — Boxed Warning & Contraindications, 2025 accessdata.fda.gov ↗FDA drug label; basis for the thyroid C-cell tumor Boxed Warning and MTC/MEN 2 contraindication.
- 02 FDA Prescribing Information, Zepbound (tirzepatide) — Indications, Warnings & Adverse Reactions, 2023 accessdata.fda.gov ↗FDA drug label; BMI criteria, warnings and precautions, and most common side effects.
- 03 STEP 1 trial (Wilding et al.), NEJM 2021 acc.org ↗Randomized trial of semaglutide 2.4 mg for weight loss, summarized by the American College of Cardiology.
- 04 SURMOUNT-1 trial (Jastreboff et al.), NEJM 2022 pubmed.ncbi.nlm.nih.gov ↗Randomized trial of tirzepatide 5/10/15 mg for weight loss (PubMed record).
- 05 SELECT trial (Lincoff et al.), NEJM 2023 pubmed.ncbi.nlm.nih.gov ↗Cardiovascular-outcomes trial of semaglutide 2.4 mg in overweight/obesity without diabetes (PubMed record).
- 06 FDA safety communication on compounded GLP-1s and consumer telehealth red flags.
- 07 FDA statement on resolved shortages and limits on compounded copies.
- 08 FDA warning letter citing compounded semaglutide and investigational retatrutide products.
- 09 FDA safety communication on counterfeit and falsely labeled semaglutide; fill at state-licensed pharmacies.
- 10 American Diabetes Association, Standards of Care in Diabetes—2025, Section 8, Diabetes Care diabetesjournals.org ↗Clinical guideline ranking semaglutide/tirzepatide efficacy and advising continued therapy to prevent weight regain.
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
